# ClinicFlow steering update and incomplete decision log

Meeting: August 20, 2026
Decision deadline: September 4, 2026
Proposed pilot start: September 8, 2026

What the group agrees on:

- Reducing intake friction is valuable.
- The September grant review creates pressure but does not override clinical safety requirements.
- A narrow, read-only pilot is acceptable if it produces useful workflow evidence.
- Medication and allergy information must not be changed without an authorized clinical approval path.
- Duplicate EHR records are a stop condition, not merely a usability defect.

What remains unresolved:

- Priya still assumes an intake coordinator can use the vendor admin override.
- Dr. Chen says that assumption conflicts with policy and has not accepted clinical accountability.
- Compliance has not approved a new role or reason-code workflow.
- The vendor has not demonstrated idempotent retry behavior.
- Legal has not approved the SMS consent text.
- Finance has not approved spending above $45,000.

Provisional sequence, not yet approved:

1. Hold the 25-minute clinical safety review with Dr. Chen, Luis Ortega, Samir Patel, and the vendor.
2. Record one accountable clinical owner, exactly who may approve medication/allergy corrections, the required audit event, and the stop condition.
3. Run a 20-record offline/retry test and reject the connector if any duplicate is produced.
4. Ask legal for a yes/no decision on the SMS language and identity exception.
5. Re-price a 30-patient, read-only pilot that stays under $45,000.
6. Make the September 4 go/no-go decision.

The steering group did not make the launch decision. The phrase “pilot approved in principle” in the sponsor's earlier email means only that the team may continue due diligence. It must not be treated as final launch approval.

The smallest question most likely to change the immediate plan is whether a named clinical owner will accept responsibility under a correction workflow that complies with medication and allergy policy. If the answer is no, the all-patient launch should stop and the team should consider only a read-only research pilot. If the answer is yes, duplicate prevention and consent approval become the next gates.

